Detalhe da pesquisa
1.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Lancet Oncol
; 23(1): 149-160, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902335
2.
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.
JAMA Oncol
; 10(2): 227-235, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991778
3.
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease.
NPJ Breast Cancer
; 9(1): 10, 2023 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878909
4.
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
NPJ Breast Cancer
; 8(1): 80, 2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35817765
5.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Clin Cancer Res
; 27(14): 3896-3904, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33602685